Which antihypertensive agents are safe to use in a patient with stage 4 chronic kidney disease (estimated glomerular filtration rate approximately 15–29 mL/min/1.73 m²)?

Safe Antihypertensive Agents for CKD Stage 4

In CKD stage 4 (eGFR 15-29 mL/min/1.73 m²), ACE inhibitors or ARBs remain the cornerstone first-line agents, particularly with albuminuria, and should be continued even at this advanced stage unless specific contraindications arise. 1, 2

First-Line Agents

RAS Inhibitors (ACEi/ARB)

• Continue ACEi or ARB even when eGFR falls below 30 mL/min/1.73 m² 2
• These are strongly recommended for patients with:
  • Moderately-to-severely increased albuminuria (A2-A3) with diabetes (1B recommendation) 1, 2
  • Severely increased albuminuria (A3) without diabetes (1B recommendation) 1, 2
  • Even without albuminuria, RASi can be reasonable for specific indications like heart failure 2

Key monitoring parameters:

• Check BP, creatinine, and potassium within 2-4 weeks of initiation or dose increase 1, 2
• Continue therapy unless creatinine rises >30% within 4 weeks 1, 2
• Use highest tolerated approved dose to achieve proven trial benefits 1, 2

When to reduce or stop:

• Consider discontinuation only for: symptomatic hypotension, uncontrolled hyperkalemia despite treatment, or to reduce uremic symptoms when eGFR <15 mL/min/1.73 m² 1, 2
• Hyperkalemia should be managed with potassium-lowering measures rather than stopping RASi when possible 1, 2

Second and Third-Line Agents

Calcium Channel Blockers

• Dihydropyridine CCBs (e.g., amlodipine) are safe and effective at all CKD stages 3, 4
• Particularly useful for BP control and cardiovascular protection 4
• Should be combined with RASi in proteinuric patients, not used as monotherapy 5

Diuretics

• Chlorthalidone is specifically effective in stage 4 CKD and represents an important option for resistant hypertension 3, 6
• Loop diuretics are often necessary at this stage, particularly when combined with thiazide-like diuretics 3
• Thiazide diuretics alone become less effective as GFR declines, but chlorthalidone maintains efficacy 6

Fourth-Line and Resistant Hypertension

Mineralocorticoid Receptor Antagonists

• Spironolactone is preferred when eGFR ≥30 mL/min/1.73 m² 3
• At stage 4 CKD, use with extreme caution due to hyperkalemia risk 1
• Can be combined with chlorthalidone to mitigate hyperkalemia, but requires careful monitoring 6

Beta-Blockers

• Safe in CKD stage 4, particularly indicated for cardiac comorbidities 3

Centrally Acting Agents

• Represent a valuable alternative for resistant hypertension 3

Emerging Disease-Modifying Agents

SGLT2 Inhibitors

• Recommended for adults with CKD and eGFR ≥20 mL/min/1.73 m² with albuminuria ≥200 mg/g or heart failure (1A recommendation) 2
• Once initiated, reasonable to continue even if eGFR falls below 20 mL/min/1.73 m² 2
• Provide cardiovascular benefits and may attenuate long-term renal decline in stage 4 CKD 7
• Initial eGFR "dip" is expected and not an indication to discontinue 2

Non-Steroidal MRAs and Other Novel Agents

• Ocedurenone, aprocitentan, and baxdrostat show promise but require more long-term safety data 6
• GLP-1 receptor agonists demonstrate antihypertensive effects with renal and cardiovascular benefits 3

Critical Pitfalls to Avoid

Never combine ACEi + ARB + direct renin inhibitor - this triple combination is contraindicated (1B recommendation) 1

Do not automatically stop RASi at stage 4 CKD - this is a common error; guidelines explicitly state to continue unless specific contraindications develop 2

Avoid systolic BP <120 mmHg - overly aggressive BP lowering risks renal hypoperfusion and adverse cardiovascular outcomes 3

Target Blood Pressure

Target office BP <130/80 mmHg for most CKD patients, though <140/90 mmHg is acceptable 3, 8. The more stringent <130/80 mmHg target is particularly important with albuminuria, diabetes, or high cardiovascular risk 3.